Cytek Biosciences Inc
NASDAQ:CTKB
Cytek Biosciences Inc
NASDAQ:CTKB
Price:
4.45
USD
0.23%
Market Closed
Market Cap:
$569m
Income Statement
Earnings Waterfall
Cytek Biosciences Inc
Cytek Biosciences Inc
Income Statement
Cytek Biosciences Inc
Cytek Biosciences Inc
Currency: USD
| Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Interest Expense |
1
|
2
|
2
|
2
|
2
|
3
|
3
|
2
|
2
|
2
|
2
|
2
|
1
|
0
|
1
|
1
|
1
|
0
|
|
| Revenue |
89
N/A
|
128
+44%
|
139
+8%
|
148
+7%
|
155
+4%
|
164
+6%
|
166
+1%
|
176
+6%
|
183
+4%
|
193
+5%
|
201
+4%
|
198
-2%
|
201
+2%
|
200
0%
|
197
-2%
|
196
-1%
|
197
+0%
|
201
+2%
|
|
| Gross Profit | |||||||||||||||||||
| Cost of Revenue |
(34)
|
(49)
|
(54)
|
(59)
|
(59)
|
(63)
|
(64)
|
(70)
|
(77)
|
(84)
|
(89)
|
(89)
|
(91)
|
(89)
|
(89)
|
(89)
|
(92)
|
(97)
|
|
| Gross Profit |
56
N/A
|
79
+42%
|
85
+7%
|
90
+6%
|
95
+6%
|
101
+6%
|
102
+1%
|
105
+4%
|
106
+0%
|
109
+3%
|
111
+2%
|
109
-2%
|
111
+2%
|
111
+1%
|
108
-3%
|
107
-1%
|
105
-1%
|
104
-1%
|
|
| Operating Income | |||||||||||||||||||
| Operating Expenses |
(48)
|
(70)
|
(79)
|
(89)
|
(96)
|
(103)
|
(113)
|
(125)
|
(133)
|
(137)
|
(138)
|
(134)
|
(134)
|
(132)
|
(133)
|
(134)
|
(137)
|
(145)
|
|
| Selling, General & Administrative |
(30)
|
(45)
|
(52)
|
(59)
|
(64)
|
(68)
|
(77)
|
(85)
|
(90)
|
(93)
|
(94)
|
(93)
|
(94)
|
(92)
|
(94)
|
(95)
|
(100)
|
(108)
|
|
| Research & Development |
(17)
|
(24)
|
(27)
|
(30)
|
(32)
|
(35)
|
(37)
|
(41)
|
(43)
|
(44)
|
(44)
|
(42)
|
(41)
|
(39)
|
(39)
|
(38)
|
(37)
|
(36)
|
|
| Operating Income |
8
N/A
|
9
+20%
|
6
-40%
|
1
-83%
|
(1)
N/A
|
(2)
-216%
|
(12)
-545%
|
(20)
-71%
|
(28)
-39%
|
(28)
-1%
|
(26)
+5%
|
(26)
+2%
|
(24)
+8%
|
(21)
+13%
|
(25)
-21%
|
(27)
-8%
|
(32)
-18%
|
(40)
-27%
|
|
| Pre-Tax Income | |||||||||||||||||||
| Interest Income Expense |
(1)
|
(2)
|
(2)
|
(2)
|
(0)
|
2
|
4
|
5
|
5
|
4
|
4
|
4
|
5
|
10
|
10
|
9
|
7
|
2
|
|
| Non-Reccuring Items |
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
1
|
3
|
5
|
7
|
8
|
7
|
5
|
7
|
5
|
7
|
11
|
9
|
9
|
|
| Pre-Tax Income |
6
N/A
|
6
+7%
|
2
-58%
|
(2)
N/A
|
(2)
-11%
|
1
N/A
|
(4)
N/A
|
(10)
-116%
|
(16)
-62%
|
(16)
+0%
|
(16)
+0%
|
(16)
-4%
|
(12)
+27%
|
(6)
+52%
|
(8)
-40%
|
(8)
+5%
|
(15)
-105%
|
(30)
-93%
|
|
| Net Income | |||||||||||||||||||
| Tax Provision |
(1)
|
(3)
|
(2)
|
(0)
|
0
|
1
|
2
|
4
|
2
|
4
|
4
|
(1)
|
2
|
(0)
|
(3)
|
1
|
3
|
(37)
|
|
| Income from Continuing Operations |
4
|
3
|
1
|
(3)
|
(2)
|
3
|
(2)
|
(6)
|
(14)
|
(12)
|
(12)
|
(18)
|
(10)
|
(6)
|
(11)
|
(6)
|
(13)
|
(67)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
0
N/A
|
0
N/A
|
(2)
N/A
|
(2)
-12%
|
(1)
+58%
|
3
N/A
|
(2)
N/A
|
(6)
-171%
|
(14)
-136%
|
(12)
+14%
|
(12)
+5%
|
(18)
-52%
|
(10)
+42%
|
(6)
+41%
|
(11)
-87%
|
(6)
+43%
|
(13)
-100%
|
(67)
-419%
|
|
| EPS (Diluted) |
0
N/A
|
0
N/A
|
-0.02
N/A
|
-0.02
N/A
|
-0.01
+50%
|
0.02
N/A
|
-0.02
N/A
|
-0.05
-150%
|
-0.11
-120%
|
-0.09
+18%
|
-0.09
N/A
|
-0.14
-56%
|
-0.08
+43%
|
-0.05
+38%
|
-0.09
-80%
|
-0.05
+44%
|
-0.1
-100%
|
-0.52
-420%
|
|
Switch to:
Switch to:
See Also
Discover More
